Literature DB >> 30053909

Associations of high-altitude polycythemia with polymorphisms in PIK3CD and COL4A3 in Tibetan populations.

Xiaowei Fan1,2, Lifeng Ma1,2, Zhiying Zhang1,2, Yi Li3,4, Meng Hao3, Zhipeng Zhao1,2, Yiduo Zhao1,2, Fang Liu1,2, Lijun Liu1,2, Xingguang Luo5, Peng Cai1,2, Yansong Li1,2, Longli Kang6,7.   

Abstract

BACKGROUND: High-altitude polycythemia (HAPC) is a chronic high-altitude disease that can lead to an increase in the production of red blood cells in the people who live in the plateau, a hypoxia environment, for a long time. The most frequent symptoms of HAPC include headache, dizziness, breathlessness, sleep disorders, and dilation of veins. Although chronic hypoxia is the main cause of HAPC, the fundamental pathophysiologic process and related molecular mechanisms responsible for its development remain largely unclear yet. AIM/
METHODS: This study aimed to explore the related hereditary factors of HAPC in the Chinese Han and Tibetan populations. A total of 140 patients (70 Han and 70 Tibetan) with HAPC and 60 healthy control subjects (30 Han and 30 Tibetan) were recruited for a case-control association study. To explore the genetic basis of HAPC, we investigated the association between HAPC and both phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit delta gene (PIK3CD) and collagen type IV α3 chain gene (COL4A3) in Chinese Han and Tibetan populations. RESULTS/
CONCLUSION: Using the unconditional logistic regression analysis and the false discovery rate (FDR) calculation, we found that eight SNPs in PIK3CD and one SNP in COL4A3 were associated with HAPC in the Tibetan population. However, in the Han population, we did not find any significant association. Our study suggested that polymorphisms in the PIK3CD and COL4A3 were correlated with susceptibility to HAPC in the Tibetan population.

Entities:  

Keywords:  COL4A3; High-altitude polycythemia; PIK3CD

Mesh:

Substances:

Year:  2018        PMID: 30053909      PMCID: PMC6062892          DOI: 10.1186/s40246-018-0169-z

Source DB:  PubMed          Journal:  Hum Genomics        ISSN: 1473-9542            Impact factor:   4.639


Introduction

High-altitude polycythemia (HAPC) is a chronic high-altitude disease, characterized by excessive erythrocytosis. The clinical HAPC is diagnosed by a hemoglobin concentration ≥ 19 g/dL for females and ≥ 21 g/dL for males, according to the criteria established in the VI World Congress on Mountain Medicine and High-altitude Physiology in 2004 [1]. More than 140 million people are living at high altitudes above 2500 m worldwide, majorly in the Andes, Ethiopian Highlands, and Qinghai-Tibet Plateau [2]. The Qinghai-Tibet Plateau is the highest plateau in the world, which covers a large area with low oxygen in natural environment, and millions of people are living and working in this region. It is well known that the body’s hemoglobin concentration increases due to the hypoxic environment of high altitude, and therefore, this response is crucial for people who adapt to live at high altitudes. Some studies show that a number of populations suffer from chronic mountain sickness because they stay long at high altitudes [3]. HAPC mainly leads to a significant increase in blood viscosity, causing damage to microcirculatory and immune response disturbances such as vascular thrombosis, extensive organ damage, and sleep disorders [4, 5]. It is reported that the prevalence of HAPC in the Qinghai-Tibet Plateau is around 5 to 18% [1], and the prevalence of HAPC increases with the altitude. As the construction of the Qinghai-Tibet Railway has been completed, a number of Han populations migrate to Tibet. The incidence of HAPC among immigrants is significantly higher than the high-altitude natives [6]. As the Tibetan population keeps genetic adaptations, they can easily adapt to the high-altitude hypoxia environment, for example, showing lower hemoglobin levels and lower hematocrit. Many studies have noted that there are some significant differences in the genomes between immigrants and high-altitude natives, which indicates that genetic factors may contribute to the development of HAPC, although the molecular mechanisms and pathogenesis are still under study. In our study, we aimed to investigate the associations between susceptibility to HAPC and two new candidate genes that are related to the oxygen metabolism in red blood cells but have not been reported before. The first candidate, PIK3CD, encodes the p110δ catalytic subunit of phosphoinositide 3-kinaseδ (PI3Kδ), a member of a big family of metalloenzymes. PI3Kδ is a heterodimer comprising the p110δ and p85 family regulatory subunit and expressed predominantly in leukocytes. Therefore, it plays an important role in the proliferation, survival, and activation of leukocytes [7-9]. The expression pattern and functions of PIK3CD are very important in PI3K/Akt pathway. Recently, research studies revealed that PI3K/Akt mediated the stabilization of HIF-1α (hypoxia-inducible factors-1α) [10], and it was also involved in the increase of HIF-1α protein level [11]. Meanwhile, HIF-1α plays an important role in transcriptionally upregulating erythropoietin (EPO) in hypoxia and affecting the amount of red blood cells [12]. The second candidate, COL4A3, encodes a subunit of type IV collagen that is a structural protein of the alveolar extracellular matrix (ECM) and mostly found in the kidney, lung, and basement membranes. It is located at 2q35-q3 and mainly contains 51 exons [13]. Type IV collagen is involved in various physiological conditions, including aging, diabetes, kidney disease, scarring, and pulmonary fibrosis [14]. The ECM is important to the structure and function of cell types. It contributes to many processes, such as cellular proliferation, differentiation, migration, and apoptosis [15].

Results

The demographics of HAPC patients and controls are shown in Table 1. The basic characteristics of candidate SNPs in the Han and Tibetan subjects are summarized in Table 2 (Fig. 1) and Table 3 (Fig. 2). We analyzed the associations between SNPs and HAPC using unconditional logistic regression analysis. In the Han population, rs72633866 (P1 = 0.033 before adjustment and P2 = 0.014 after adjustment for age), rs9430220 (P1 = 0.081 and P2 = 0.029), rs199962152 (P1 = 0.024 and P2 = 0.034), and rs10864435 (P1 = 0.013 and P2 = 0.002) in PIK3CD were significantly associated with HAPC. In the Tibetan subjects, rs2230735 (P1 = 0.008 and P2 = 0.008), rs28730671 (P1 = 0.007 and P2 = 0.007), rs111888887 (P1 = 0.034 and P2 = 0.034), rs28730674 (P1 = 0.007 and P2 = 0.007), rs371870925 (P1 = 0.007 and P2 = 0.007), rs199962152 (P1 = 0.045 and P2 = 0.040), rs77571929 (P1 = 0.005 and P2 = 0.005), rs117226273 (P1 = 0.007 and P2 = 0.007), rs28730676 (P1 = 0.007 and P2 = 0.007), and rs28730677 (P1 = 0.007 and P2 = 0.007) in PIK3CD were significantly associated with HAPC. Furthermore, rs34505188 (P1 = 0.028 and P2 = 0.028), rs11677877 (P1 = 0.013 and P2 = 0.013), rs34019152 (P1 = 0.018 and P2 = 0.018), and rs28381984 (P1 = 0.001 and P2 = 0.001) in COL4A3 were associated with HAPC.
Table 1

Demographics of the control individuals and patients with high-altitude polycythemia

VariablesHanTibetan
Case (n = 70)Control (n = 30)Case (n = 70)Control (n = 30)
Male35153515
Female35153515
Table 2

Basic information of candidate SNPs in Han subjects

SNP_IDGeneAlleles A/BCase (N)Control (N)OR (95% CI) P P1P2
AAABBBAAABBB
rs7518602PIK3CDC/T4165006233.899 (1.515–10.290)0.9610.2610.425
rs7516138PIK3CDG/A41947011184.150 (1.615–10.989)0.9930.9590.800
rs7516214PIK3CDG/A41946011184.070 (1.582–10.786)0.9930.9240.829
rs11805716PIK3CDT/C13173239143.610 (1.335–10.014)0.9610.5160.488
rs11806839PIK3CDG/C711122662.800 (0.640–12.570)0.9930.6270.616
rs79190623PIK3CDC/T637023603.952 (1.533–10.448)0.7660.1600.245
rs72633866PIK3CDG/A644022605.107 (1.892–14.498)0.2360.0330.014
rs2230735PIK3CDA/G637023603.952 (1.533–10.448)0.7660.1600.245
rs182137610PIK3CDA/C637024503.961 (1.540–10.444)0.9610.3210.510
rs188191807PIK3CDG/A573023304.280 (1.564–12.125)0.9610.2870.486
rs28730671PIK3CDC/T655023603.808 (1.463–10.129)0.5090.0610.129
rs111888887PIK3CDT/C655024503.816 (1.471–10.117)0.8210.1410.312
rs9430220PIK3CDT/C3728491825.044 (1.871–14.464)0.2450.0810.029
rs28730674PIK3CDA/G655023603.808 (1.463–10.129)0.5090.0610.129
rs371870925PIK3CDT/C653024504.016 (1.520–10.884)0.5090.0500.112
rs199962152PIK3CDA/G632022503.065 (1.118–8.502)0.2450.0240.034
rs77571929PIK3CDT/C645023603.737 (1.439–9.970)0.5090.0650.132
rs117226273PIK3CDG/T655023603.808 (1.439–10.129)0.5090.0610.129
rs28730676PIK3CDT/C655023603.808 (1.436–10.129)0.5090.0610.129
rs10864435PIK3CDC/T637020906.247 (2.235–18.787)0.0510.0130.002
rs28730677PIK3CDG/A655024503.816 (1.471–10.117)0.8210.1410.312
rs10178458COL4A3T/C096104254.116 (1.069–10.826)0.9930.9000.803
rs6436669COL4A3A/G096104254.116 (1.069–10.826)0.9930.9000.803
rs80109666COL4A3G/A4919222703.984 (1.545–10.552)0.9930.4330.707
rs55703767COL4A3G/T5315221714.088 (1.600–10.732)0.9930.7320.762
rs10205042COL4A3C/T2155317214.073 (1.592–10.704)0.9930.7320.869
rs34505188COL4A3G/A46195181104.214 (1.637–11.199)0.9930.7870.587
rs11677877COL4A3A/G46195171204.187 (1.625–11.138)0.9930.9970.725
rs34019152COL4A3G/A46195181104.214 (1.637–11.199)0.9930.7870.587
rs28381984COL4A3C/T27321191644.160 (1.623–10.984)0.9930.7110.599

SNP single-nucleotide polymorphism, OR odds ratio, 95% CI 95% confidence interval, P value FDR-calculated P value, P1 P value calculated by unconditional logistic regression analysis, P2 P value adjusted for age

Fig. 1

Forest plots for the ORs in the Han population

Table 3

Basic information of candidate SNPs in Tibetan subjects

SNP_IDGeneAlleles A/BCase (N)Control (N)OR (95% CI) P P1P2
AAABBBAAABBB
rs7518602PIK3CDC/T52936110191.043 (0.438–2.490)0.6120.2400.238
rs7516138PIK3CDG/A112633313141.015 (0.428–2.411)0.9920.7350.733
rs7516214PIK3CDG/A112632313140.992 (0.416–2.366)0.9820.6880.691
rs11805716PIK3CDT/C15271768131.061 (0.416–2.718)0.5550.2070.206
rs11806839PIK3CDG/C5742931.205 (0.270–5.393)0.8930.5930.612
rs79190623PIK3CDC/T58101181110.862 (0.349–2.106)0.0810.0180.018
rs72633866PIK3CDG/A578125201.071 (0.434–2.656)0.7910.3660.367
rs2230735PIK3CDA/G59101171210.844 (0.337–2.079)0.0460.0080.008
rs182137610PIK3CDA/C5710118910.764 (0.301–1.897)0.1500.0500.045
rs188191807PIK3CDG/A535122500.685 (0.266–1.726)0.7910.4540.396
rs28730671PIK3CDC/T6361191010.821 (0.324–2.035)0.0460.0070.007
rs111888887PIK3CDT/C616121810.906 (0.368–2.205)0.1300.0340.034
rs9430220PIK3CDT/C29345121440.940 (0.395–2.234)0.8510.5360.535
rs28730674PIK3CDA/G6361191010.821 (0.324–2.035)0.0460.0070.007
rs371870925PIK3CDT/C644120910.812 (0.320–2.017)0.0460.0070.007
rs199962152PIK3CDA/G584119610.685 (0.256–1.766)0.1460.0450.040
rs77571929PIK3CDT/C6351191010.814 (0.320–2.024)0.0460.0050.005
rs117226273PIK3CDG/T6361191010.821 (0.324–2.035)0.0460.0070.007
rs28730676PIK3CDT/C6361191010.821 (0.324–2.035)0.0460.0070.007
rs10864435PIK3CDC/T5515025411.011 (0.423–2.417)0.9920.8790.878
rs28730677PIK3CDG/A6361191010.821 (0.324–2.035)0.0460.0070.007
rs10178458COL4A3T/C4214547191.026 (0.432–2.442)0.8510.5390.537
rs6436669COL4A3A/G4214547191.026 (0.432–2.442)0.8510.5390.537
rs80109666COL4A3G/A609128201.070 (0.449–2.559)0.6550.2710.267
rs55703767COL4A3G/T4721218840.990 (0.415–2.360)0.5240.1840.184
rs10205042COL4A3C/T0234748181.017 (0.425–2.437)0.3050.1020.102
rs34505188COL4A3G/A42208101460.948 (0.390–2.292)0.1150.0280.028
rs11677877COL4A3A/G42217101370.941 (0.385–2.290)0.0700.0130.013
rs34019152COL4A3G/A42208101370.928 (0.380–2.254)0.0810.0180.018
rs28381984COL4A3C/T2439723610.761 (0.294–1.928)0.0350.0010.001

The abbreviations were the same as Table 2

Fig. 2

Forest plots for the ORs in the Tibetan population

Demographics of the control individuals and patients with high-altitude polycythemia Basic information of candidate SNPs in Han subjects SNP single-nucleotide polymorphism, OR odds ratio, 95% CI 95% confidence interval, P value FDR-calculated P value, P1 P value calculated by unconditional logistic regression analysis, P2 P value adjusted for age Forest plots for the ORs in the Han population Basic information of candidate SNPs in Tibetan subjects The abbreviations were the same as Table 2 Forest plots for the ORs in the Tibetan population After using FDR to correct for multiple comparisons, in the Tibetan subjects, we found that rs2230735 (OR = 0.844, 95% CI = 0.337–2.079, P = 0.046), rs28730671 (OR = 0.821, 95% CI = 0.324–2.035, P = 0.046), rs28730674 (OR = 0.821, 95% CI = 0.324–2.035, P = 0.046), rs371870925 (OR = 0.812, 95% CI = 0.320–2.017, P = 0.046), rs77571929 (OR = 0.814, 95% CI = 0.320–2.024, P = 0.046), rs117226273 (OR = 0.821, 95% CI = 0.324–2.035, P = 0.046), rs28730676 (OR = 0.821, 95% CI = 0.324–2.035, P = 0.046), rs28730676 (OR = 0.821, 95% CI = 0.324–2.035, P = 0.046), and rs28730677 (OR = 0.821, 95% CI = 0.324–2.035, P = 0.046) in PIK3CD were significantly associated with HAPC. Furthermore, rs28381984 (OR = 0.761, 95% CI = 0.294–1.928, P = 0.035) in COL4A3 was associated with HAPC in the Tibetan population. But in the Han population, we did not find any significant association. In addition, using haplotype analysis, two blocks were detected among the PIK3CD SNPs (Fig. 3): block 1 contains rs7518602, rs7516138, rs7516214, and rs11805716 and block 2 contains rs79190623, rs72633866, rs2230735, rs182137610, rs188191807, rs28730671, rs111888887, rs9430220, rs28730674, rs371870925, rs199962152, rs77571929, rs117226273, rs28730676, rs10864435, and rs28730677. Two blocks were detected among the COL4A3 SNPs too (Fig. 4): block 1 contains rs10178458 and rs6436669 and block 2 contains rs55703767, rs10205042, rs34505188, rs11677877, and rs34019152. These SNPs within the same genes showed strong linkage in-between.
Fig. 3

Haplotype block map for the 15 PIK3CD SNPs

Fig. 4

Haplotype block map for the 21 COL4A3 SNPs

Haplotype block map for the 15 PIK3CD SNPs Haplotype block map for the 21 COL4A3 SNPs

Discussion

Tibet covers a vast area with a harsh hypoxic natural environment. According to a report in 2006, approximately 12 million people permanently settled down in this region. This number constantly increases every year; the increase mainly comes from the Han population that are emigrating from plain areas [16]. HAPC is a serious disease that threatens the health of people in the plateau area, especially those who have emigrated from a low-altitude area. In the past, a large number of patients with HAPC have been investigated with a focus on the pathophysiologic mechanisms of this disease. Nevertheless, a lot of questions remain to be elucidated. With the completion of the human genome project, much research has been shifted to human genetic variation, which was one of NIH’s Roadmap Initiatives for 2008 [17]. As we all know, in Tibet, in order to adapt to altitude hypoxia, the body increases the hemoglobin concentration to increase the efficiency of carrying oxygen, and this response is crucial for the Han population who adapt to live at high altitudes. Compared with the Han people, the Tibetan population keeps genetic adaptations; they can easily adapt to the high-altitude hypoxia environment. Several studies have indicated that natural selection associated with high-altitude adaptation appears to act on genes in the hypoxic response pathway to regulate erythrocyte production, possibly to prevent or reduce erythrocyte growth [18-22]. Recently, significant progress has been made in the study of the genetic basis of HAPC in Tibetans and Han, and some studies have confirmed that many genes are associated with HAPC. Namely, integrin subunit alpha 6 (ITGA6), erb-b2 receptor tyrosine kinase 4 (ERBB4), EPH receptor A2 (EPHA2), angiotensinogen (AGT), and endothelial PAS domain protein 1 (EPAS1) have been reported to play important roles in HAPC in Tibetans and Han [23-26]. Of these genes, EPHA2 can affect erythrocyte production by regulating EPO production and EPAS1 has been implicated as making the greatest contribution to genetic adaptation to high altitude and to the low Hb concentrations observed in the Tibetan population [18, 21]. Some research have shown that genetic variants selected for adaptation at extreme environmental conditions not only increase cancer risk later on age but may also be the downregulation of erythropoiesis in Tibetans in high altitude [22, 27, 28]. In our study, we found rs2230735, rs28730671, rs28730674, rs371870925, rs77571929, rs117226273, rs28730676, rs28730677, and rs28381984 in PIK3CD and COL4A3 were significantly associated with decreased HAPC risk in the Tibetan population. However, in the Han population, we did not find any significant association. Inspired by the development of genome research and the genetic findings of high-altitude natives, we consider that genetic factors may be involved in the formation of such kind of disease. Our study revealed an association of HAPC with SNPs in PIK3CD and COL4A3 in the Tibetan population. PIK3CD gene encodes P110δ catalytic subunit that is expressed predominantly in leukocytes and plays a vital role in the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. According to recent reports, p110δ contributes to the activation of Akt and cell proliferation in primary AML (acute myeloid leukemia) cells [29, 30]. PI3K signaling contributes to many processes, including cell cycle progression, proliferation and differentiation, survival, and migration [8, 9, 31]. PI3K/Akt pathways are critical to HIF-1α transcriptional activity in hypoxia. HIF-1, which is basically a heterodimer transcription factor, composed of HIF-1α and HIF-1β subunits, serves as a central regulator of metabolic adaptation to low oxygen [32]. The HIF-1α subunit is stabilized under hypoxia, translocating to the nucleus, forming a heterodimer with HIF-1β, and transactivating its target genes including EPO. HIF-1α is a factor that was originally thought to be bound to the 3′ enhancer region of the EPO genes, controlling for 100–200 genes that are involved in angiogenesis, glycolysis, and erythropoiesis [33]. The main organ for EPO production is the liver during the fetus stage, whereas it becomes the kidney after birth. However, there is small amount of expression in the other organs of the body, such as the brain, spleen, lungs, testis, and placenta. Further, it is a necessary glycoprotein, which does not only promote the maturation of red blood cell from erythroid progenitors but also mediates erythropoiesis. It is identified as an inducer of erythropoiesis and can promote excessive cell production. In addition, previous studies showed that inhibited PI3K/Akt signaling pathway led to decreased hematopoietic stem cell (HSC) proliferation. This suggests that such kind of pathway is important for HSC proliferation. HSC is involved in the formation of HAPC, expansion of the population, and enforcement of erythroid lineage-committed differentiation [34]. Therefore, we speculate that PIKCD may affect the generation of EPO and the decrease of HSC appreciation through the PI3K/Akt signaling pathway. In this study, we show here for the first time that the PIK3CD gene plays a crucial role in the production of erythrocyte, so PIK3CD has a significant influence on the formation of HAPC. COL4A3 is an important risk gene for HAPC that is also linked to many diseases such as the Alport syndrome, focal segmental glomerulosclerosis, and type 2 diabetes [35-37]. Furthermore, it is important to the structure and function of various cell types and contributes to a variety of processes. Although the functional effects of the polymorphisms have not yet been elucidated fully, our current results show that the variants may have an effect on COL4A3 expression or activity. Therefore, it may play an important role in modulating the susceptibility to HAPC. By searching the KEGG pathway database, we found that COL4A3 can bind to receptors on cell surface and promote the activation of PI3K/Akt. Under hypoxic conditions, this pathway can promote the production of hypoxia-inducible factor and increase the cell cycle, and thereby promote the increase of EPO and the amount of red blood cells. Therefore, it is speculated that COL4A3 may affect the production of EPO through the PI3K/Akt signaling pathway, thus affecting the production of red blood cells. Consequently, COL4A3 gene may be a useful marker for the formation of HAPC. We also show here for the first time that the COL4A3 gene plays a crucial role in the production of erythrocyte. Meanwhile, based on the results of our research, COL4A3 was significantly associated with erythropoiesis in hypoxia. It is suggested that gene polymorphisms may be relevant to the susceptibility to HAPC. The genome research era has also opened the road to studying the basis of susceptibility to chronic mountain sickness (CMS) [38]. Gene polymorphisms have set the platform for the analysis of the molecular mechanisms of adaptation to life at high altitudes [39]. Tibet, an average elevation above 4000 m, is commonly regarded as the “Roof of the World” and has a unique genetic background and dietary and lifestyle habits. In this study, we have suggested that several genetic polymorphisms are associated with susceptibility to HAPC and each polymorphism may contribute to only a small relative risk of HAPC. It shows a complex interplay between exposure to hypoxic environmental stimuli and genetic background. There are important discoveries revealed by the studies, but there are still a lot of limitations. Due to these limitations, the study power of this paper is limited. On the other hand, the functions of the genetic variants and their mechanisms have not been evaluated in this study. In a following study, we will use animal models to verify the experimental results, to more clearly illustrate how the two genes affect erythrocytosis, which signaling pathways are involved in the formation of the disease, and to try to elucidate the functions of the genetic variants and mechanisms with HAPC.

Conclusion

We analyzed SNPs in PIK3CD and COL4A3 and identified a relationship between genetic polymorphisms and HAPC in the Tibetan people. This study sets out to improve the quality of life of people living in the Qinghai-Tibet Plateau, determines paramount insights into the etiology of HAPC, and may provide more guidance for such people with regard to prolonged and healthy living. However, additional genetic risk factors and functional investigations should be identified in order to further confirm our results.

Materials and methods

Study populations

A total of 140 patients (70 Han and 70 Tibetan) with HAPC and 60 healthy control subjects (30 Han and 30 Tibetan) were recruited for a case-control association study. The 200 subjects who participated in this research had resided at an altitude of above 4000 m, and these samples were collected from the General Hospital in Tibet Military Region and the second People’s Hospital of Tibet Autonomous Region. Written informed consent was obtained from each individual. Patients met the diagnostic criteria for HAPC, i.e., males with hemoglobin ≥ 21 g/dL or females with hemoglobin ≥ 19 g/dL, and had no high-altitude cerebral edema and chronic respiratory disorders or secondary polycythemia due to hypoxemia caused by certain chronic diseases. Moreover, subjects have no endocrinological, nutritional, and metabolic diseases. Healthy individuals were randomly selected as controls. The experimental protocol was established by the Ethics Committee of the Xizang Minzu University.

Epidemiological and clinical data

We used a standardized epidemiological questionnaire to collect demographic and clinical data, including information on gender, age, residential region, ethnicity, family history of cancer, and education status. Furthermore, the patient information was collected through physicians or from medical chart review. All participants signed informed consent, and 5 ml of peripheral blood was taken from each participant in this study.

Selection of SNPs and methods of genotyping

Thirty SNPs from PIK3CD and COL4A3 were chosen for analysis in this study, including 21 SNPs in PIK3CD and 9 SNPs in COL4A3 with minor allele frequency (MAF) > 0.05 in the Asian population HapMap database, and SNP genotyping was performed utilizing Illumina sequencing platform for exon sequencing of PIKCD and COL4A3. Because the genetic background of Han and Tibetan populations has not been compared yet, we selected these two candidate genes based on their relations to the oxygen metabolism in red blood cells, which were related to high-altitude adaptation in the Chinese Han and Tibetan populations.

Statistical analysis

The data were analyzed using an R program, Haploview, and Excel. Unconditional logistic regression analysis was used to calculate odds ratios (ORs), 95% confidence intervals (CIs), and P values for comparisons between cases and controls. Multiple comparisons were corrected using FDR, and FDR-corrected P < 0.05 was considered to indicate a significant difference.
  36 in total

1.  Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders.

Authors:  Cynthia M Beall; Gianpiero L Cavalleri; Libin Deng; Robert C Elston; Yang Gao; Jo Knight; Chaohua Li; Jiang Chuan Li; Yu Liang; Mark McCormack; Hugh E Montgomery; Hao Pan; Peter A Robbins; Kevin V Shianna; Siu Cheung Tam; Ngodrop Tsering; Krishna R Veeramah; Wei Wang; Puchung Wangdui; Michael E Weale; Yaomin Xu; Zhe Xu; Ling Yang; M Justin Zaman; Changqing Zeng; Li Zhang; Xianglong Zhang; Pingcuo Zhaxi; Yong Tang Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 2.  Chronic mountain sickness: recent studies of the relationship between hemoglobin concentration and oxygen transport.

Authors:  John T Reeves; Fabiola Leon-Velarde
Journal:  High Alt Med Biol       Date:  2004       Impact factor: 1.981

Review 3.  High altitude adaptation in Tibetans.

Authors:  Tianyi Wu; Bengt Kayser
Journal:  High Alt Med Biol       Date:  2006       Impact factor: 1.981

4.  Sequencing of 50 human exomes reveals adaptation to high altitude.

Authors:  Xin Yi; Yu Liang; Emilia Huerta-Sanchez; Xin Jin; Zha Xi Ping Cuo; John E Pool; Xun Xu; Hui Jiang; Nicolas Vinckenbosch; Thorfinn Sand Korneliussen; Hancheng Zheng; Tao Liu; Weiming He; Kui Li; Ruibang Luo; Xifang Nie; Honglong Wu; Meiru Zhao; Hongzhi Cao; Jing Zou; Ying Shan; Shuzheng Li; Qi Yang; Peixiang Ni; Geng Tian; Junming Xu; Xiao Liu; Tao Jiang; Renhua Wu; Guangyu Zhou; Meifang Tang; Junjie Qin; Tong Wang; Shuijian Feng; Guohong Li; Jiangbai Luosang; Wei Wang; Fang Chen; Yading Wang; Xiaoguang Zheng; Zhuo Li; Zhuoma Bianba; Ge Yang; Xinping Wang; Shuhui Tang; Guoyi Gao; Yong Chen; Zhen Luo; Lamu Gusang; Zheng Cao; Qinghui Zhang; Weihan Ouyang; Xiaoli Ren; Huiqing Liang; Huisong Zheng; Yebo Huang; Jingxiang Li; Lars Bolund; Karsten Kristiansen; Yingrui Li; Yong Zhang; Xiuqing Zhang; Ruiqiang Li; Songgang Li; Huanming Yang; Rasmus Nielsen; Jun Wang; Jian Wang
Journal:  Science       Date:  2010-07-02       Impact factor: 47.728

5.  Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.

Authors:  Pierre Sujobert; Valerie Bardet; Pascale Cornillet-Lefebvre; Joel S Hayflick; Nolwen Prie; Frederic Verdier; Bart Vanhaesebroeck; Odile Muller; Florence Pesce; Norbert Ifrah; Mathilde Hunault-Berger; Christian Berthou; Bruno Villemagne; Eric Jourdan; Bruno Audhuy; Eric Solary; Brigitte Witz; Jean Luc Harousseau; Chantal Himberlin; Thierry Lamy; Bruno Lioure; Jean Yves Cahn; Francois Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Blood       Date:  2005-04-19       Impact factor: 22.113

6.  COL4A3 mutations cause focal segmental glomerulosclerosis.

Authors:  Jingyuan Xie; Xiaoxi Wu; Hong Ren; Weiming Wang; Zhaohui Wang; Xiaoxia Pan; Xu Hao; Jun Tong; Jun Ma; Zhibin Ye; Guoyu Meng; Yufei Zhu; Krzysztof Kiryluk; Xiangyin Kong; Landian Hu; Nan Chen
Journal:  J Mol Cell Biol       Date:  2014-12       Impact factor: 6.216

7.  Association of COL4A3 (rs55703767), MMP-9 (rs17576)and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes.

Authors:  Samira Saravani; Davood Yari; Ramin Saravani; Changiz Azadi Ahmadabadi
Journal:  Biomed Rep       Date:  2017-02-09

8.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

9.  PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.

Authors:  Jie Zhou; Tobias Schmid; Ronald Frank; Bernhard Brüne
Journal:  J Biol Chem       Date:  2004-01-15       Impact factor: 5.157

10.  Associations of high altitude polycythemia with polymorphisms in EPHA2 and AGT in Chinese Han and Tibetan populations.

Authors:  Lijun Liu; Yao Zhang; Zhiying Zhang; Yiduo Zhao; Xiaowei Fan; Lifeng Ma; Yuan Zhang; Haijin He; Longli Kang
Journal:  Oncotarget       Date:  2017-06-06
View more
  6 in total

1.  Targeted Sequencing Identifies the Genetic Variants Associated with High-altitude Polycythemia in the Tibetan Population.

Authors:  Zhiying Zhang; Lifeng Ma; Xiaowei Fan; Kun Wang; Lijun Liu; Yiduo Zhao; ZhiPeng Zhao; Han Zhang; Tian Liang; Wenxue Dong; Peng Cai; Yansong Li; Jing Li; Songhua Zhou; Longli Kang
Journal:  Indian J Hematol Blood Transfus       Date:  2021-08-03       Impact factor: 0.915

2.  Identification of hub genes in chronically hypoxic myocardium using bioinformatics analysis.

Authors:  Fan Wu; Feng Gao; Siyi He; Yingbin Xiao
Journal:  Mol Med Rep       Date:  2019-03-01       Impact factor: 2.952

Review 3.  Metabonomics window into plateau hypoxia.

Authors:  Yue Chang; Wen Zhang; Kai Chen; Zhenguo Wang; Shihai Xia; Hai Li
Journal:  J Int Med Res       Date:  2019-10-09       Impact factor: 1.671

4.  Safety and Efficacy of Therapeutic Erythrocytapheresis Treatment in Chronic Mountain Sickness Patients in Shigatse, Tibet, China.

Authors:  Mingyuan Niu; Shekhar Singh; Ma Mi; Pian Bian; Zhuoga Deji; Duoji Mima; Xiankai Li
Journal:  Med Sci Monit       Date:  2020-12-23

5.  Microarray-Based Prediction of Polycythemia after Exposure to High Altitudes.

Authors:  Haijing Wang; Daoxin Liu; Pengfei Song; Feng Jiang; Tongzuo Zhang
Journal:  Genes (Basel)       Date:  2022-07-02       Impact factor: 4.141

6.  The impact of COVID-19 on populations living at high altitude: Role of hypoxia-inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication.

Authors:  Christian Albert Devaux; Didier Raoult
Journal:  Front Physiol       Date:  2022-08-25       Impact factor: 4.755

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.